Bradley J . Monk, MD

Professor

photo placeholder for Monk, Bradley J

Contact

School of Medicine
Obstetrics and Gynecology Residency
Arizona Health

Bradley J . Monk, MD

Professor

Department

Obstetrics & Gynecology (Phoenix)

Position

Professor

Books

  • Clinical Gynecologic Oncology
    Chase Dana M., Wong Siu-Fun, Wenzel Lari B., Monk Bradley J., 20 - Palliative Care and Quality of Life [Book Chapter] 2018

Publications

  • Journal of clinical oncology
    Konstantinopoulos Panagiotis A, Paule Ines, Sufliarsky Jozef, Hinson Patsy, Zuradelli Monica, Wang Craig, Su Fei, Miller Michelle, Matulonis Ursula A, González-Martín Antonio, Grisham Rachel N, Kim Jae Weon, Freyer Gilles, Lee Jung Yun, Gaba Lydia, Colombo Nicoletta, Cibula David, Wu Xiaohua, Sehouli Jalid, Cruz Felipe, Lorusso Domenica, Monk Bradley J, Nyvang Gitte-Bettina, Friedlander Michael, Marth Christian, Van Nieuwenhuysen Els, Malik Rozita, Glasspool Rosalind, Marmé Frederik, Leary Alexandra, Cortés-Salgado Alfonso, Zamagni Claudio, Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation, p. JCO2500225 2025
  • Journal of clinical oncology
    Banerjee Susana N, Oaknin Ana, Van Nieuwenhuysen Els, Aghajanian Carol, D'Hondt Véronique, Monk Bradley J, Clamp Andrew, Prendergast Emily, Rodrigues Manuel, Ring Kari, Colombo Nicoletta, Holloway Robert W, Thaker Premal H, Chon Hye Sook, Gourley Charlie, Santin Alessandro D, Youssoufian Hagop, Gennigens Christine, Newman Gregg, Salinas Erin, Van Gorp Toon, Moore Kathleen N, Lustgarten Stephanie, O'Malley David M, Grisham Rachel N, , Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2500112 2025
  • Gynecologic oncology
    Chan John K., McHale Michael T., Tewari Krishnansu, Monk Bradley J., Herzog Thomas J., Coleman Robert L., Richardson Michael T., Salani Ritu, Francoeur Alex A., Kapp Daniel S., Optimizing therapy for cervical cancers – Translating trial data into clinical decision-making
    199, p. 47 - 50 2025
  • The Lancet (British edition)
    Olawaiye Alexander B, Artioli Grazia, Gladieff Laurence, O'Malley David M, Kim Jae-Weon, Garbaos Gabriel, Salutari Vanda, Caruso Giuseppe, Nicum Shibani, Bagaméri Andrea, Kesner-Hays Amanda, Bodnar Lubomir, Kang Sokbom, Vergote Ignace, Jubb Adrian M, Pashova Hristina I, Pai Sachin G, Tudor Iulia Cristina, Hopp Elizabeth, Gilbert Lucy, Mileshkin Linda, Devaux Alix, Lorusso Domenica, Kim Byoung-Gie, Lee Yong Jae, Oaknin Ana, Scaranti Mariana, Clamp Andrew, Colombo Nicoletta, McCollum Michael E, Diakos Connie, Scandurra Giuseppa, Leiser Aliza L, Balázs Boglárka, Monk Bradley J, De La Cueva Helena, McClung Emily, Kaczmarek Emilie, Slomovitz Brian, de Carvalho Calabrich Aknar Freire, Churruca Cristina, Cassani Chiara, You Benoit, Van Gorp Toon, Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial 2025
  • Annals of oncology
    Mayadev J, Dry H, Estevez-Diz M D P, Limaye S, Xin W, Kahán Z, Vera L, Rey F, Santini A, Leiva M, Vázquez Limón J C, Ramírez Godinez F J, Cetina-Pérez L D C, Wu X, Shapira-Frommer R, Galaz P, Meléndez Mier G, Mandai M, Varga S, Molina Alavez A, Alarcon-Rozas A E, Valdiviezo N, Acevedo C, Figueroa A, Monk B J, Broggi M A S, Yuan D Y, Stewart R A, Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses 2025
  • Journal of clinical oncology
    Bujnak Alyssa, Birrer Michael J., Hamilton Alina, Sill Michael, Monk Bradley J., Hari Anjali, Penson Richard T., Lankes Heather A., Hoadley Katherine A., Liu Hongwei, Szot Christopher, Ramondetta Lois M., Oaknin Ana, Leitao Mario Mendes, Copeland Larry J., Ramirez Nilsa C., Wei Lei, Tewari Krishnansu Sujata, miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot
    43:16_suppl, p. 5523 - 5523 2025
  • International journal of gynecological cancer
    Lightfoot Michelle DS, Moore Kathleen N., Eskander Ramez N., Herzog Thomas J., Pothuri Bhavana, Rubinstein Maria M., Monk Bradley J., Lutz Kathleen, Oral Mucositis Associated with Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment, p. 101997 2025
  • International journal of gynecological cancer
    Secord Angeles Alvarez, Alvarez Ronald D., Mutch David, Randall Leslie M., Mannel Robert S., Small Michelle N., Coleman Robert L., Herzog Thomas J., Monk Bradley J., Moore Kathleen N., Copeland Larry J., Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: The GOG Foundation, Inc.’s Scholar Career Development Award and New Investigator Program, p. 101982 2025
  • Journal of clinical oncology
    Shahin Mark S., Moore Richard G., Hietanen Sakari, O’Cearbhaill Roisin E., Mangili Giorgia, Berton Dominique, Rubio-Pérez Maria Jesús, Burger Robert Allen, Braicu Elena Ioana, Monk Bradley J., Shtessel Luda, Cloven Noelle, Aaquist Haslund Charlotte, Herzog Thomas J, Lim Jonathan, Gonzalez Martin Antonio, McCormick Colleen C., Barretina-Ginesta Maria-Pilar, O’Malley David M., Honhon Brigitte, Impact of disease progression on health-related quality of life (HRQOL): Updated results from the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (aOC)
    43:16_suppl, p. 5551 - 5551 2025
  • Journal of clinical oncology
    Mayadev Jyoti, Vázquez Limón Juan Carlos, RamIrez Godinez Francisco Javier, Leiva Manuel, Alarcon-Rozas Ashley Efrain, Cetina Lucely Del Carmen, Varga Szilvia, Molina Alavez Alejandro, Valdivieso Natalia, Wu Xiaohua, Limaye Sewanti Atul, Mandai Masaki, Shapira-Frommer Ronnie, Estevez-Diz Maria Del Pilar, Xin Wenjing, Broggi Maria, Stewart Ross, Monk Bradley J., Yuan Daniel Y., Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses
    43:16_suppl, p. 5502 - 5502 2025
  • Journal of clinical oncology
    Salani Ritu, Lin Zhongqiu, Lindemann Kristina, Mirza Mansoor Raza, Nishio Shin, Cáceres Valeria, Oaknin Ana, Kurtz Jean Emmanuel, Valabrega Giorgio, Harter Philipp, Van Gorp Toon, Gilbert Lucy, Sadozye Azmat, De Rêgo Barros Lilian Arruda, Boere Ingrid A., Marth Christian, Duska Linda R., Monk Bradley J., Li Xin Tong, Tekin Cumhur, , TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer
    43:16_suppl 2025
  • Journal of clinical oncology
    Mercieca-Bebber Rebecca, Lee Yeh Chen, Barnes Elizabeth H., Moore Kathleen N., Fyles Anthony, Narayan Kailash, Khaw Pearly, Buck Martin, Brooks Susan, Holschneider Christine, Lea Jayanthi Sivasothy, Stuckey Ashley, Lad Thomas E., Spirtos Nicola M., Stockler Martin R., Boyd Leslie R., Small William, Monk Bradley J., Mileshkin Linda R., King Madeleine T., Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial
    43:16_suppl, p. 5503 - 5503 2025
  • ESMO open
    Oaknin A., Littell R., Fujiwara K., Kristeleit R., Monk B.J., Prendergast E., Salutari V., Schenker M., Martinez-Garcia J., Yeku O., Ueland F., Lee J-Y., De Vivo R., Dean A., Diaz J., Bese T., Jewell A., Van Gorp T., Maloney L., 75MO Efficacy and safety of rucaparib maintenance treatment in patients from ATHENA-MONO/GOG-3020/ENGOT-ov45 with newly diagnosed advanced ovarian cancer not associated with homologous recombination deficiency
    10 2025
  • ESMO open
    Okines A., Oh D-Y., Curigliano G., Mizuno N., Rorive A., Hamilton E.P., Soliman H., Takahashi S., Bekaii-Saab T., Monk B.J., Nakamura Y., Ramos J.D., Nguyen D., O'Malley D., Reck M., Yu E., Drees A., Tan Q., Stinchcombe T., Pohlmann P.R., 304MO Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019)
    10, p. 104876 2025
  • International journal of gynecological cancer
    Podder Vivek, Cobb Lauren Patterson, Grisham Rachel N., Coleman Robert L., Slomovitz Brian M., Monk Bradley J., Herzog Thomas, Gershenson David M., Repurposing FDA-Approved Cancer Therapies: Exploring Endocrine and Targeted Pathways in Low-Grade Serous Ovarian Cancer Treatment, p. 101938 2025
  • Cancer treatment reviews
    Monk Bradley J., Sehouli Jalid, Lorusso Domenica, Fujiwara Keiichi, Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review, p. 102945 2025
  • Gynecologic oncology
    Matulonis Ursula A., Mahner Sven, Berton Dominique, Berek Jonathan S., Redondo Andrés, Herrstedt Jørn, Oza Amit, Lindahl Gabriel, Haslund Charlotte A., Marmé Frederik, Tinker Anna V., Ledermann Jonathan A., Benigno Benedict, Mirza Mansoor R., Bains Manjinder, González-Martín Antonio, Bécourt Stéphanie, Colombo Nicoletta, Malinowska Izabela A., Liu Wenlei, Monk Bradley J., ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
    195, p. 192 2025
  • Gynecologic oncology
    Leath, 3rd Charles A, Holman Laura L, Deng Wei, Mell Loren K, Richardson Debra L, Walker Joan L, Arend Rebecca C, Lea Jayanthi S, Amarnath Sudha R, Santos-Reyes Luis Javier, Chon Hye Sook, Mayadev Jyoti, Jegadeesh Naresh, DiSilvestro Paul, Chino Junzo P, Ghamande Sharad A, Gao Lei, Albuquerque Kevin, Quick Allison M, Donnelly Eric, Feddock Jonathan M, Lowenstein Jessica, Kunos Charles M, MacKay Helen, Aghajanian Carol, Monk Bradley J, Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
    195, p. 122 - 133 2025
  • Gynecologic oncology
    Carter Jeanne, Huang Helen Q, Monk Bradley J, Vicus Danielle L, Kim Yong-Beom, Kim Moon-Hong, Stuckey Ashley, Thawani Nitika, Holman Laura L, Fleury Aimee C, Pearson J Matthew, Feltmate Colleen, Shahin Mark, Lea Jayanthi, Robertson Sharon E, Warshal David, Backes Floor J, Wilkinson-Ryan Ivy, Covens Allan, Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278)
    195, p. 50 2025
  • Gynecologic oncology
    Covens Allan, Kim Moon-Hong, DiSilvestro Paul, Monk Bradley J, Kim Yong-Beom, Huang Helen Q, Robertson Sharon E, Fleury Almee, Pearson J Matthew, Thawani Nitika, Vicus Danielle, Holman Laura L, Shahin Mark S, Lea Jayanthi S, Wilkinson-Ryan Ivy, Feltmate Colleen, Dewdney Summer, Leitao Mario M, Elsayed Ahmed G, Carter Jeanne, Backes Floor, Warshal David, Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)
    195, p. 59 2025
  • European journal of cancer (1990)
    Vergote Ignace, Thaker Premal H., Van Gorp Toon, Laenen Annouschka, Scambia Giovanni, Cibula David, Colombo Nicoletta, Lea Jayanthi, Monk Bradley J., Gonzalez-Martin Antonio, Korach Jacob, Sehouli Jalid, Heinzelmann-Schwarz Viola, Berger Regina, Buscema Joseph, Lau Susie, Mądry Radoslaw, Denys Hannelore, Pepin Jessica Thomes, Salutari Vanda, Bagaméri Andrea, Ardizzoia Antonio, Copeland Larry J., Henry Stéphanie, Cecere Sabrina Chiara, Hruda Martin, Iglesias David A., Manso Luis, Shai Ayelet, O’Malley David M., Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study, p. 115306 2025
  • International journal of gynecological cancer
    Lorusso Domenica, Pothuri Bhavana, Monk Bradley J., Barretina-Ginesta Maria-Pilar, Vergote Ignace, O’malley David M., Haslund Charlotte A., Heitz Florian, O’cearbhaill Roisin E., Abadie-Lacourtoisie Sophie, Backes Floor J., Chase Dana M., Amit Amnon, Moore Kathleen N., Malinowska Izabela A., Graybill Whitney S., Herzog Thomas J., Golembesky Amanda K., Rubio Pérez Maria-Jesús, González-Martín Antonio, Updated Patient-Reported Outcomes In The PRIMA/ENGOT-OV26/GOG-3012 Trial Of Niraparib First-Line Maintenance Therapy In Patients With Newly Diagnosed Advanced Ovarian Cancer
    35:2, p. 100093 2025
  • Gynecologic oncology
    Bogani Giorgio, Lorusso Domenica, Moore Kathleen N., Ray-Coquard Isabelle, Matulonis Ursula A., Caruso Giuseppe, Ledermann Jonathan A., González-Martín Antonio, Kurtz Jean-Emmanuel, Pujade-Lauraine Eric, Scambia Giovanni, Raspagliesi Francesco, Colombo Nicoletta, Monk Bradley J., Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
    193, p. 30 - 40 2025
  • International journal of gynecological cancer
    Leitao Mario M., Randall Leslie M., Lim Peter C., Bixel Kristin L., Chase Dana Meredith, Quick Allison, McCormick Colleen, Black Destin, Eskander Ramez N., Martino Martin A., Walker Joan L., Copeland Larry J., Monk Bradley J., Gotlieb Walter H., LoCoco Salvatore, ROCC/GOG-3043: A randomized controlled trial of robotic versus open surgery for early-stage cervical cancer, p. 101760 2025
  • International journal of gynecological cancer
    Salani Ritu, Lindemann Kristina, Lin Zhongqiu, Valabrega Giorgio, Nishio Shin, Oaknin Ana, Kurtz Jean-Emmanuel, Cáceres M. Valeria, Harter Philipp, Van Gorp Toon, Gilbert Lucy, Sadozye Azmat H., Do Rêgo Barros Lilian Arruda, Boere Ingrid, Marth Christian, Mirza Mansoor Raza, Monk Bradley J., Li Xin Tong, Tekin Cumhur, Duska Linda, TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer
    35:2, p. 100497 2025
  • International journal of gynecological cancer
    Ghamande Sharad, Prendergast Emily, Miller Rowan E., Solovyeva Ekaterina, Del Mar Gordon Santiago Maria, Kim Yong-Man, Littell Ramey, Fujiwara Keiichi, Anttila Maarit, Connor Christy, Craib Marcia, Monk Bradley J., Kristeleit Rebecca S., Turna Hande, Ruiz Nuria, Bessette Paul, Van Le Linda, Westin Shannon N., Zvaríková Mária, Eskander Ramez N., ATHENA-MONO Post-Progression Survival Data Update In Patients With Newly Diagnosed Advanced Ovarian Cancer
    35:2, p. 100319 2025
  • International journal of gynecological cancer
    Lokich Elizabeth, Jørgensen Trine Lembrecht, Black Destin, Cibula David, Gilbert Lucy, Savarese Antonella, Powell Matthew A., Herbertson Rebecca, Gill Sarah E., Monk Bradley J., Nevadunsky Nicole, Cloven Noelle, Podzielinski Iwona, Myers Tashanna, Dabrowski Christine, Ring Kari L., Stevens Shadi, Willmott Lyndsay, Mirza Mansoor Raza, Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial
    35:2, p. 101722 2025
  • American journal of obstetrics and gynecology
    Levin Gabriel, Pothuri Bhavana, Monk Bradley J, Coleman Robert, Zeng Xing, Herzog Thomas, Gilbert Lucy, Bernard Laurance, Scalia Peter, Slomovitz Brian, Racial and ethnic enrollment disparities in clinical trials leading to FDA approvals for gynecologic malignancies, p. - 2025
  • Nature medicine
    Okines Alicia F C, Curigliano Giuseppe, Mizuno Nobumasa, Takahashi Shunji, Oh Do-Youn, Rorive Andree, Soliman Hatem, Hamilton Erika P, Bekaii-Saab Tanios, Burkard Mark E, Chung Ki Y, Debruyne Philip R, Fox Jenny R, Gambardella Valentina, Gil-Martin Marta, Monk Bradley J, Olawaiye Alexander B, Nakamura Yoshiaki, Nguyen Danny, O'Malley David M, Sunakawa Yu, Pothuri Bhavana, Reck Martin, Sudo Kazuki, Van Marcke Cedric, Bieda Mark, Yu Evan Y, Ramos Jorge, Tan Sherry, Stinchcombe Thomas E, Pohlmann Paula R, Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial 2025
  • European journal of cancer (1990)
    Oaknin Ana, Gotovkin Evgeniy, Monk Bradley J, Lorusso Domenica, Damian Fernanda, Chang Chih-Long, Pikiel Joanna, Goh Jeffrey C, Hasegawa Kosei, Mora Paulo, Srivastav Ratnesh, Colombo Nicoletta, Fury Matthew G, Tewari Krishnansu S, Polastro Laura, Alia Eva Maria Guerra, Makarova Yulia, Rischin Danny, Rubio Maria Jesús, Perez Javier, Seebach Frank, Yoo Suk Young, Gao Bo, Jamil Shaheda, Lowy Israel, Samouëlian Vanessa, de Melo Andreia Cristina, Kim Hee Seung, Takahashi Shunji, Ramone Daniella, Maćkowiak-Matejczyk Beata, Kim Yong Man, Lisyanskaya Alla S, Mathias Melissa, Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
    216, p. 115146 2025
  • Nature reviews. Clinical oncology
    Francoeur Alex A, Tewari Krishnansu S, Monk Bradley J, Treatment advances across the cervical cancer spectrum 2025
  • Mirza Mansoor R, Chase Dana M, Slomovitz Brian M, Gilbert Lucy, Coleman Robert L, Powell Matthew A, Christensen René de Pont, Novák Zoltán, Black Destin, Sharma Sudarshan, Valabrega Giorgio, Landrum Lisa M, Hanker Lars C, Stuckey Ashley, Boere Ingrid, Gold Michael A, Auranen Annika, Raspagliesi Francesco, Pothuri Bhavana, Cibula David, McCourt Carolyn, Shahin Mark S, Gill Sarah E, Monk Bradley J, Stevens Shadi, Copeland Larry J, Tian Min, He Zangdong, Buscema Joseph, Herzog Thomas J, Zografos Eleftherios, A Plain Language Summary of “Dostarlimab for primary advanced or recurrent endometrial cancer” 2025
  • Journal of comparative effectiveness research
    Graybill Whitney S, Heitz Florian, Willmott Lyndsay J, Bruchim Ilan, Zhuo Ying, Pothuri Bhavana, Anttila Maarit, O'Malley David M, Lorusso Domenica, Estévez-García Purificación, Monk Bradley J, Denys Hannelore, Knudsen Anja, Tinker Anna V, Haggerty Ashley F, Fabbro Michel, Chan John K, Vergote Ignace, Sánchez Luis Manso, Provencher Diane, Barretina-Ginesta Maria Pilar, Hartman John, Booth Donna V, González-Martín Antonio, Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
    14:1, p. e240133 2025
  • J Comp Eff Res
    Graybill Whitney S, Vergote Ignace, Pothuri Bhavana, Anttila Maarit, O'Malley David M, Lorusso Domenica, Haggerty Ashley F, Fabbro Michel, Chan John K, Heitz Florian, Willmott Lyndsay J, Bruchim Ilan, Zhuo Ying, Sánchez Luis Manso, Provencher Diane, Estévez-García Purificación, Monk Bradley J, Denys Hannelore, Knudsen Anja, Tinker Anna V, Barretina-Ginesta Maria Pilar, Hartman John, Booth Donna V, González-Martín Antonio, Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
    14:1, p. e240133 2025
  • Journal of gynecologic oncology
    Kim Yong-Man, Tewari Krishnansu S., Hasegawa Kosei, Dubot Coraline, Cáceres M. Valeria, Lorusso Domenica, Kim Se Ik, Lee Jeong-Won, Liou Wen-Shiung, Li Kan, Nishio Shin, Tekin Cumhur, Colombo Nicoletta, Monk Bradley J., Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
    36 2025
  • Annals of oncology
    González-Martín A, Malinowska I A, Monk B J, Reply to Letter to the Editor 'Long-term outcomes in the PRIMA trial: a closer look at PFS and OS' by Wu et al 2024
  • Cancer research communications
    Zhang Hailei, Mirza Mansoor R, Monk Bradley J, Vergote Ignace, Graybill Whitney A Spannuth, Goessel Carsten, Barbash Olena, Bergamini Giovanna, Pothuri Bhavana, Feng Bin, González-Martín Antonio, Rutkowska Anna, Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials 2024
  • Cancer Res Commun
    Zhang Hailei, Monk Bradley J, Rutkowska Anna, González-Martín Antonio, Mirza Mansoor R, Vergote Ignace, Pothuri Bhavana, Graybill Whitney A. Spannuth, Goessel Carsten, Barbash Olena, Bergamini Giovanna, Feng Bin, Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials 2024
  • Oncology and therapy
    Monk Bradley J., Tekin Cumhur, Keefe Steve, Monberg Matthew, Muston Dominic, Boer Jennifer, van Mens Sophie, Hale Oliver, van Hees Frank, Swami Shilpi, Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States 2024
  • Gynecologic oncology
    Grisham Rachel, Lustgarten Stephanie, Thaker Premal, Oza Amit, Colombo Nicoletta, Denis Louis, O'Malley David, Banerjee Susana, Monk Bradley, Nieuwenhuysen Els, Moore Kathleen, Fabbro Michel, Oaknin Ana, A phase III, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of therapy among patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-OV81/NCRI/RAMP 301
    190, p. S282 - S283 2024
  • Gynecologic oncology
    Banerjee Susana, Moore Kathleen, Clamp Andrew, Ray-Coquard Isabelle, Chon Hye Sook, Salinas Erin, Monk Bradley, Rose Peter, O'Malley David, Oaknin Ana, Holloway Robert, Gennigens Christine, Moroney John, Van Gorp Toon, Kalbacher Elsa, Newman Gregg, Van Nieuwenhuysen Els, Colombo Nicoletta, Wojtynek Nicholas, Lustgarten Stephanie, Grisham Rachel, Santin Alessandro, Ring Kari, Thaker Premal, Prendergast Emily, Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/RAMP 201 Part A
    190, p. S55 - S56 2024
  • Gynecologic oncology
    Moore Kathleen, Williams Dennis, Musa Fernanda, Nathenson Michael, Sauer Amy, Jolliffe Darren, Rosenberg Marisa, Norry Elliot, Monk Bradley, Ray-Coquard Isabelle, Oaknin Ana, Coleman Robert, Rose Peter, Herzog Thomas, O'Malley David, Lheureux Stephanie, Morris Robert, Starks David, Lanneau Grainger, GOG-3084: A phase II trial of ADP-A2M4CD8 TCR-T cell therapy, alone or in combination with nivolumab, among patients with recurrent ovarian cancers
    190, p. S281 - S282 2024
  • Gynecologic oncology
    Graybill Whitney, Haggerty Ashley, Fabbro Michel, Chan John, Heitz Florian, Willmott Lyndsay, Bruchim Ilan, Zhuo Ying, Estévez-García Purificación, Monk Bradley, Denys Hannelore, Vergote Ignace, Pothuri Bhavana, Anttila Maarit, O'Malley David, Lorusso Domenica, Knudsen Anja, Tinker Anna, Sánchez Luis Manso, Provencher Diane, Barretina-Ginesta M. Pilar, Hartman John, Booth Donna, González-Martín Antonio, Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
    190, p. S274 - S275 2024
  • Gynecologic oncology
    Pothuri Bhavana, Oaknin Ana, Monk Bradley, Graybill Whitney, Sánchez Ana Beatriz, Levy Tally, York Whitney, Malinowska Izabela, González-Martín Antonio, Denys Hannelore, McCormick Colleen, Baurain Jean-François, Tinker Anna, O'Cearbhaill Roisin, de La Motte Rouge Thibault, Hietanen Sakari, Moore Richard, Knudsen Anja, Heitz Florian, Valabrega Giorgio, Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
    190, p. S295 - S296 2024
  • Gynecologic oncology
    Hunsberger Kyra, Tewari Krishnansu, Randall Leslie, Chase Dana, Monk Bradley, Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis
    190, p. S421 - S421 2024
  • Gynecologic oncology
    Kristeleit Rebecca, Miller Rowan, Monk Bradley, O'Malley David, Lim Myong Cheol, Coleman Robert, Herzog Thomas, Wilson Michelle, De Vivo Rocco, Oaknin Ana, Chudecka-Glaz Anita, Oza Amit, Mikheeva Olga, Buscema Joseph, Van Le Linda, Morris Robert, Van Gorp Toon, Moore Kathleen, Zagouri Flora, Shih Danny, Rob Lukáš, Craib Marcia, Connor Christy, Fujiwara Keiichi, Interim post-progression data and updated survival in patients with newly diagnosed advanced ovarian cancer in ATHENA-MONO
    190, p. S10 - S11 2024
  • Gynecologic oncology
    Banerjee Susana, Roxburgh Patricia, Marsolini Diane, Westin Shannon, Eskander Ramez, Sardone Megan, Ray-Coquard Isabelle, Moore Kathleen, Berton Dominique, Monk Bradley, Van Nieuwenhuysen Els, O'Malley David, Oaknin Ana, Barlin Joyce, Anderson Charles, Redondo Andrés, Brubaker Lindsay, Ang Joo Ern, Cloven Noelle, Baurain Jean-François, A phase Ib, multicenter, open-label study of NXP800, a novel GCN2 kinase activator, among patients with platinum-resistant, ARID1A-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800-101; GOG-3087)
    190, p. S302 - S302 2024
  • Annals of oncology
    Lorusso D, Colombo N, Dubot C, Cáceres M V, Hasegawa K, Gümüş M, Shapira-Frommer R, Salman P, Yañez E, Olivera M, Toker S, Castonguay V, Arkhipov A, Li K, Samouëlian V, Tekin C, Tewari K S, Monk B J, Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study 2024
  • International journal of gynecological cancer
    Barlin Joyce, Hand Lauren, Black Destin, Cottrill Hope, Eshed Helen, Durbin Joan, O’Malley David, Chuang Linus, Chisamore Michael, Zheng Pan, Lim Peter, Pepin Jessica Thomes, Hopp Elizabeth, Cloven Noelle, Monk Bradley, Liu Yang, Shpyro Svetlana, LB010/#1590  A phase 2 randomized dose optimization trial of gotistobart, a PH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer (PROC, preserve-004/GOG-3081; NCT05446298)
    34, p. A6 - A8 2024
  • International journal of gynecological cancer
    Lorusso Domenica, Van Gorp Toon, Zagouri Flora, Bodnar Lubomir, Collins Dearbhaile, Korach Jacob, Marth Christian, Kroep Judith, Zhu Jianqing, Hasegawa Kosei, Samouëlian Vanessa, Lee Jung-Yun, Casarotto Fernanda, Antill Yoland, Chase Dana, Shahin Mark, Orlowski Robert, Woodhouse Kristina, Cui Yi, Willmott Lyndsay, Monk Bradley, TP003/#1538  Phase 3 ENGOT-en23/GOG-3095/MK-2870–005 study: sacituzumab tirumotecan (Sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who received prior chemotherapy and immunotherapy
    34, p. A348 - A348 2024
  • International journal of gynecological cancer
    Grisham Rachel, O’Malley David, Monk Bradley, Van Nieuwenhuysen Els, Moore Kathleen, Fabbro Michel, Colombo Nicoletta, Oaknin Ana, Thaker Premal, Oza Amit, Lustgarten Stephanie, Youssoufian Hagop, Banerjee Susana, PR029/#943  A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301
    34, p. A53 - A54 2024
  • International journal of gynecological cancer
    Bixel Kristin, Lee Sun Joo, Baiocchi Glauco, Black Destin, Eskander Ramez, Gotlieb Walter, Lococo Salvatore, Randall Leslie, Martino Martin, Mccormick Colleen, Monk Bradley, Quick Allison, Walker Joan, Leitao Mario, Chase Dana, TP001/#1584  GOG-3043 (nct04831580): a randomized non-inferiority trial of robotic versus open surgery for early stage cervical cancer (ROCC)
    34, p. A347 - A347 2024
  • International journal of gynecological cancer
    Oaknin Ana, Lorusso Domenica, Lee Jung-Yun, Pietzner Klaus, Auranen Annika, Cibula David, Lee Yeh Chen, Schilder Russell, Gao Bo, Salutari Vanda, Tan David, Oza Amit, Miller Rowan, Pothuri Bhavana, Tasca Giulia, O’Malley David, Monk Bradley, Wendel Naumann R., Lu Lin, Berman Craig, Borgman Anne, TP010/#1537  Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: the reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study
    34, p. A351 - A351 2024
  • International journal of gynecological cancer
    Banerjee Susana, Youssoufian Hagop, Kalbacher Elsa, Van Gorp Toon, Lustgarten Stephanie, Van Nieuwenhuysen Els, Grisham Rachel, Aghajanian Carol, Santin Alessandro, Ring Kari, Colombo Nicoletta, Chon Hye Sook, Thaker Premal, Prendergast Emily, Moore Kathleen, Cortés-Salgado Alfonso, Clamp Andrew, O’malley David, Monk Bradley, Fabbro Michel, LB007/#1548  Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
    34, p. A13 - A13 2024
  • European journal of cancer (1990)
    Nakamura Y., Monk B.J., Bekaii-Saab T., Hayashi H., Mizuno N., Nguyen D., Hamilton E., Okines A., O’Malley D.M., Pohlmann P.R., Pothuri B., Reck M., Sudo K., Drees A., Sunakawa Y., Takahashi S., Yu E.Y., Tan S., Stinchcombe T.E., 3 Oral: Tucatinib and Trastuzumab for Patients With Previously Treated, HER2- Altered Solid Tumors (SGNTUC-019): A Phase 2 Basket Study
    211, p. 114532 2024
  • Annals of oncology
    Monk B.J., Vergote I., Shahin M.S., González-Martín A., Graybill W., Mirza M.R., McCormick C.C., Lorusso D., Heitz F., Moore R.G., Freyer G., O’Cearbhaill R.E., O’Malley D.M., Redondo A., Vulsteke C., Chase D.M., Barretina-Ginesta M.P., Pothuri B., Bradley W.H., Haslund C.A., Pisano C., DiSilvestro P., Gaba L., Holman L.L., Pérez M. J. Rubio, Shtessel L., Herzog T.J., Bruchim I., Compton N., Malinowska I.A., Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
  • International journal of gynecological cancer
    Vergote Ignace, Valabrega Giorgio, Monk Bradley J, Herzog Thomas, Perez Fidalgo Alejandro, Antill Yoland, Colombo Nicoletta, Cibula David, Pothuri Bhavana, Sehouli Jalid, Korach Jacob, Barlin Joyce, Papadimitriou Christos A, van Gorp Toon, Richardson Debra, McCarthy Michael, Mirza Mansoor Raza, Li Kai, Kalyanapu Pratheek, Slomovitz Brian, Coleman Robert L, ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: ratio
    34:8, p. 1283 2024
  • ESMO open
    Kristeleit R., O'Malley D., Lim M-C., McNeish I., Coleman R.L., Monk B.J., Herzog T.J., Wilson M., Fehm T.N., Van Gorp T., Lisyanskaya A.S., Oza A.M., Mikheeva O., Buscema J., Lindahl G., Shih D., Gao B., Lorusso D., Morgan M., Fujiwara K., 49MO Updated progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) treated with rucaparib (RUC) in ATHENA-MONO
    9, p. 103556 2024
  • Gynecologic oncology
    Pothuri Bhavana, Van Le Linda, Burger Robert A., Gaba Lydia, Guerra Eva, Bender David, Baurain Jean-François, Korach Jacob, Cloven Noelle, Churruca Cristina, Follana Philippe, DiSilvestro Paul, Bacqué Emeline, Jardon Kris, Pisano Carmela, Peen Ulla, Mäenpää Johanna, Gupta Divya, Li Yong, Compton Natalie, Antonova Jenya, Monk Bradley J., González-Martín Antonio, Heitz Florian, Han Sileny, Chase Dana M., Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
    184, p. 168 - 177 2024
  • Chan John, Richardson Michael, Tian Chunqiao, Monk Bradley, McNally Leah, Kesterson Joshua, Lin Ken, Darcy Kathleen, Kapp Daniel, Landrum Lisa, Copeland Larry, Berry Laurel, Bell Jeffery, Spirtos Nick, Walker Joan, Wenham Robert, Phippen Neil, Tewari Krishnansu, Shahin Mark, Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study 2024
  • Gynecologic oncology reports
    Rimel Bobbie J., Wang Travis, Chase Dana M., Perhanidis Jessica, Ghazarian Armen A., Du Ella Xiaoyan, Monk Bradley J., Salani Ritu, Song Jinlin, Golembesky Amanda K., Hurteau Jean A., Kalilani Linda, Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance set, p. 101332 2024
  • Gynecologic oncology
    Valabrega Giorgio, Pothuri Bhavana, Oaknin Ana, Graybill Whitney S, Sánchez Ana Beatriz, McCormick Colleen, Baurain Jean-François, Tinker Anna V, Denys Hannelore, O'Cearbhaill Roisin E, Hietanen Sakari, Moore Richard G, Knudsen Anja Ør, de La Motte Rouge Thibault, Heitz Florian, Levy Tally, York Whitney, Gupta Divya, Monk Bradley J, González-Martín Antonio, Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
  • The New England journal of medicine
    Mirza Mansoor R, Slomovitz Brian M, Chase Dana M, dePont Christensen René, Novák Zoltán, Valabrega Giorgio, Black Destin, Gilbert Lucy, Sharma Sudarshan, Landrum Lisa M, Hanker Lars C, Stuckey Ashley, Pothuri Bhavana, Boere Ingrid, Gold Michael A, Auranen Annika, Cibula David, McCourt Carolyn, Raspagliesi Francesco, Buscema Joseph, Shahin Mark S, Gill Sarah E, Monk Bradley J, Herzog Thomas J, Copeland Larry J, Tian Min, Coleman Robert L, He Zangdong, Stevens Shadi, Zografos Eleftherios, Powell Matthew A, , Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer, p. - 2023
  • Gynecologic oncology
    Chase Dana M., Romeo Marin Margarita, Backes Floor, Han Sileny, Graybill Whitney, Mirza Mansoor Raza, Pothuri Bhavana, Mangili Giorgia, O'Malley David M., Berton Dominique, Willmott Lyndsay, Baumann Klaus, Coleman Robert L., Safra Tamar, Heinzelmann-Schwarz Viola, Lorusso Domenica, Karl Florian M., Woodward Tatia, Monk Bradley J., Gonzalez-Martin Antonio, , Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial
    166:3, p. 494 - 502 2022
  • THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
    Barretina-Ginesta Maria-Pilar, Chase Dana M, Lorusso Domenica, Gupta Divya, Monk Bradley J, Auranen Annika, Han Sileny, Pothuri Bhavana, Braicu Elena, Amit Amnon, Redondo Andres, Shah Ruchit, Kebede Nehemiah, Hawkes Carol, Woodward Tatia, O'Malley David M, Gonzalez-Martin Antonio, Anderson Charles, Abadie-Lacourtoisie Sophie, Cloven Noelle, Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
    14 2022
  • Journal of clinical oncology
    Bixel Kristin Leigh, Chase Dana Meredith, Leitao Mario M., Gotlieb Walter H., Quick Allison, Lim Peter C, Eskander Ramez Nassef, LoCoco Salvatore, Walker Joan L., Martino Martin A, McCormick Colleen, Myers Tashanna K. N., Tewari Krishnansu Sujata, Slomovitz Brian M., Randall Leslie M., Copeland Larry J., Monk Bradley J., ROCC/GOG-3043: A randomized non-inferiority trial of robotic versus open radical hysterectomy for early-stage cervical cancer
    40:16_suppl, p. TPS5605 - TPS5605 2022
  • International journal of gynecological cancer
    Mäenpää Johanna, Pothuri Bhavana, Follana Philippe, Han Sileny, Chase Dana, Bender David, Bacque Emeline, Yong L I, González-Martin Antonio, Monk Bradley J, 294 Patient-reported outcomes (PROS) in patients (PTS) receiving niraparib in the prima/engot-ov26/gog-3012 trial
    30:Suppl 4, p. A63 - A64 2020
  • International journal of gynecological cancer
    Freyer G, Monk B, Pothuri B, Han S, Chase D, Heitz F, Guerra E, Burger R, Gaba L, Van Le L, Peen U, Bender D, Korach J, Baurain J F, Jardon K, Pisano C, Maenpaa J, González-Martín A, Bacque E, Li Y, Eliason L, DiSilvestro P, Cloven N, Churruca C, Follana P, Hoskins P, 17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
    30:Suppl 3, p. A12 - A13 2020
  • Gynecologic oncology
    Eakin Cortney M., Monk Bradley J., Norton Taylor J., Chase Dana M., Management of nausea and vomiting frompoly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer
    159:2, p. 581 - 587 2020
  • Heitz F, Cloven N, Monk B J, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Follana P, Maenpaa J, Baurain J F, Pisano C, Peen U, Bacque E, Li Y, Burger R, González-Martin A, Pothuri B, Han S, Chase D, Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial 2020
  • Annals of oncology
    Pothuri B., Gaba L., Han S., Chase D., Heitz F., Burger R., Van Le L., Cloven N.G., Guerra E., Bender D., Korach J., Follana P., Maenpaa J., Baurain J-F., Pisano C., Peen U., Bacqué E., Li Y., Martín A. González, Monk B.J., 810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
    31, p. S612 - S613 2020
  • International journal of gynecological cancer
    Chase Dana, Pulaski Heather L, Leitao Mario, Oaknin Ana, Huh Warner K, Robison Katina, Sill Michael W, Guntupalli Saketh R, Richardson Debra, Salani Ritu, Wenzel Lari B, Gil Karen, Tewari Krishnansu Sujata, Huang Helen Q, Monk Bradley J, Ramondetta Lois Michelle, Penson Richard T, Landrum Lisa M, Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study
    30:5, p. 596 - 601 2020
  • Gynecologic oncology
    Eakin C., Monk B., Chase D., Ewongwo A., A Qualitative Evaluation of Clinical Burden of Poly (ADP-ribose) Polymerase Inhibitor Usage in a Community Oncology Practice
    156:3, p. e23 - e24 2020
  • Scientific reports
    Łaniewski Paweł, Monk Bradley J., Greenspan David L., Cui Haiyan, Roe Denise J., Barnes Dominique, Goulder Alison, Chase Dana M., Herbst-Kralovetz Melissa M., Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis
    9:1, p. 7333 - 7333 2019
  • Gynecologic oncology
    Liang J., Stone J., Monk B.J., Wolsiefer K., Chase D.M., Evidence of provider implicit bias toward women with cervical cancer: A study of physicians and nurses caring for gynecologic oncology patients
    149, p. 137 - 137 2018
  • Journal of clinical oncology
    Tewari Krishnansu Sujata, Feng Minjie, Lheureux Stephanie, Vergote Ignace, Oaknin Ana, Alvarez Edwin, Chase Dana Meredith, Gaillard Stephanie, Rischin Danny, Santin Alessandro, Fury Matthew G., Lowy Israel, Mathias Melissa, Monk Bradley J., GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer
    36:15_suppl, p. TPS5600 - TPS5600 2018
  • Gynecologic oncology
    Moreno A., Vo Elise, Bhattarai B., Patel S., Farley J., Willmott L., Monk B., Chase D., Factors Associated with Increased Narcotic Usage after Undergoing Robotic Assisted Laparoscopy
    147:1, p. 203 - 203 2017
  • Gynecologic oncology
    Barnes Dominique, Monk Bradley J., Chase Dana, Shields Kristin M., Willmott Lyndsay J., Farley John, Patient characteristics associated with obesity in an endometrial cancer patient: first steps towards the design of a weight loss intervention
    147:1, p. 215 - 215 2017
  • Gynecologic oncology
    Barnes Dominique, Willmott Lyndsay J., Farley John, Monk Bradley J., Chase Dana, Clinic-based Depression Screening in Gynecologic Oncology Patients using the Patient Health Questionnaires-2 (PHQ-2): are we identifying the highest risk patients?
    147:1, p. 215 - 215 2017
  • Gynecologic Oncology
    Chase Dana M., Monk Bradley J., Chaplin D. J., The Development and use of Vascular Targeted Therapy in Ovarian Cancer
    145:2, p. 393 - 406 2017
  • Gynecologic oncology research and practice
    Minion Lindsey E., Chase Dana M., Farley John H., Willmott Lyndsay J., Monk Bradley J., Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study
    3:1, p. 4 - 4 2016
  • Obstetrics and gynecology (New York. 1953)
    Chase Dana M, Craig Christine D, Fedewa Stacey A, Virgo Katherine S, Farley John H, Halpern Michael, Monk Bradley J, Lin Chun Chieh, Disparities in Vulvar Cancer Reported by the National Cancer Database: Influence of Sociodemographic Factors
    126:4, p. 792 - 802 2015
  • Gynecologic oncology
    Shields K., Baxter L., Renda L., Pipe J., Craig C., Monk B., Chase D., Abstract 15: Cancer-related fatigue in gynecologic oncology patients undergoing chemotherapy
    137:3, p. 596 - 596 2015
  • Gynecologic oncology
    Shields K.M., Willmott L., Farley J.H., Monk B.J., Chase D., Factors associated with low educational background in uterine cancer patients
    137, p. 123 - 123 2015
  • Gynecologic oncology
    Chase Dana M., Wenzel Lari B., Huang Helen, Foss Cassandra D., Monk Bradley J., Burger Robert A., Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: Characteristics associated with toxicity and the effect of substitution with docetaxel: An NRG Oncology/Gynecologic Oncology Group study
    136:2, p. 323 - 327 2015
  • Gynecologic Oncology
    Osann K., Wenzel L., Hsieh S., Monk Bradley J., Chase D., Cella D., Nelson E. L., Factors associated with poor quality of life among cervical cancer survivors: implications for clinical care and clinical trials
    135:2, p. 266 - 272 2014
  • Gynecologic oncology research and practice
    Foss Cassandra D, Farley John H, Dalton Heather J, Monk Bradley J, Chase Dana M, Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
    1:1, p. 4 - 4 2014
  • International Journal of Gynecological Cancer
    Liang Winnie S., Nasser Sara, Aldrich Jessica, Kurdoglu Ahmet, McDonald Jacquelyn, Izatt Tyler, Christoforides Alexis, Baker Angela, Craig Christine, Egan Jan B., Chase Dana M., . . . Monk, Bradley J., Monk Bradley J., Phillips Lori, Reiman Rebecca, Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing
    24:2, p. 329 - 338 2014
  • Gynecologic oncology
    Craig C., Gibson S.J., Osann K.E., Farley J., Willmott L., Monk B.J., Chase D.M., The characteristics and associations of pelvic pain in gynecologic cancer patients: A single institution study
    131:1, p. 264 - 264 2013
  • Gynecologic oncology
    Craig C., Gibson S., Osann K., Farley J., Monk B., Chase D., Pelvic pain, quality of life (QOL), and exercise in gynecologic cancer patients: A single institution study
    130:1, p. e31 - e32 2013
  • Gynecologic oncology
    Craig C., Lin C., Fedewa S., Virgo K., Farley J., Monk B., Chase D., Therapeutic choices and outcomes in vulvar cancer cases reported by the National Cancer Database Registry
    130:1, p. e163 - e163 2013
  • Critical Reviews in Oncology/Hematology
    Monk Bradley J., Dalton Heather, Farley John H., Chase Dana M., Benjamin Ivor, Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
    86:2, p. 161 - 175 2013
  • European Journal of Gynaecological Oncology
    Jordan S. M., Rutgers J. K., Chase D. M., Watanabe T., Osann K., Monk Bradley J., High pathologic misdiagnosis of cervical adenocarcinoma in situ
    34:5, p. 446 - 449 2013
  • Gynecologic Oncology
    Chase Dana M., Chambers Mark D., Sill Michael W., Monk Bradley J., Darcy Kathleen M., Han Ernest S., Buening Barbara J., Sorosky Joel I., Fruehauf John P., Burger Robert A., Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory a
    126:3, p. 375 - 380 2012
  • Expert review of pharmacoeconomics & outcomes research
    Chase Dana M., Wenzel L. B., Monk Bradley J., Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer
    12:3, p. 279 - 281 2012
  • Gynecologic oncology
    Osann Kathryn, Wenzel Lari, Sappington Sandra, Dogan Aysun, Hsieh Susie, Chase Dana M., Monk Bradley J., Nelson Edward L., Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial
    121:3, p. 558 - 564 2011
  • Gynecologic oncology
    Chase D., Chambers M., Sill M., Darcy K., Buening B., Han E., Fruehauf J., Monk B., Sorosky J., Burger R., Changes in tumor blood flow as estimated by dynamic-contrast MRI may predict activity of single-agent bevacizumab in recurrent epithelial ovarian cancer and primary peritoneal cancer: An exploratory analysis of a Gynecologic Oncology Group phase II trial
    120, p. S65 - S66 2011
  • Future oncology (London, England)
    Chase Dana M., Watanabe Tawny, Monk Bradley J., Assessment and significance of quality of life in women with gynecologic cancer
    6:8, p. 1279 - 1287 2010
  • Expert review of anticancer therapy
    Chase Dana M., Tewari Krishnansu S., Monk Bradley J., Wenzel Lari B., Supportive care for women with gynecologic cancers
    8:2, p. 227 - 241 2008